whatshot

LNTH   $108.66  0.16% Market Open

Lantheus Holdings Inc
show_chart Advanced Chart of LNTH
Last Events:

2023-08-09 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Trend Power changed from slow to almost flat.

2023-08-06 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from almost flat to slow.

2023-08-05 Trend Power changed from slow to almost flat.

2023-08-04 Trend pattern changed from нисходящий треугольник to канал.

Current temperature: 7.89
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 11
Target Price Mean 144.55
Mean unverified/preliminary 144.55 / 144.55
Target Price Low / High 125.00 / 175.00
Median / STD DEV 145.00 / 14.96
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy None
rsi ActivelyBuy ActivelyBuy None
macd None None None
stoch Sell None None
ma20 ActivelyBuy ActivelyBuy None
ma50 Sell None None
ma100 ActivelyBuy ActivelyBuy None
Candlestick PatternSept. 17, 2024 Three Soldiers - is a candlestick pattern that consists of three long white candlesticks with consecutively higher closes. The closing prices are near to or at their highs. Considered to be a bullish reversal pattern.
ISIN US5165441032
ceo Mr. Brian A. Markison
Website https://www.lantheus.com
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.